Stock RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Charles River Laboratories International, Inc. Deutsche Boerse AG

Equities

RV6

US1598641074

Market Closed - Deutsche Boerse AG
Other stock markets
 01:35:05 2024-06-03 pm EDT 		5-day change 1st Jan Change
187.8 EUR -2.72% Intraday chart for Charles River Laboratories International, Inc. -6.45% -12.31%
May. 30 Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development CI
May. 15 Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
CI
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance
MT
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024
CI
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27
MT
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn
MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B
MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40
MT
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024
CI
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids
CI
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
CI
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
CI
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies
MT
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
CI
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus
MT
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement
CI
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
CI
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy
MT
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
CI
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada
CI
Charles River Laboratories International Sets Accord With Wheeler Bio on Clinical Trials
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. RV6 Stock
  5. News Charles River Laboratories International, Inc.
  6. Highlights